The study is looking at possible new medicines for weight control in people with high body weight. The study looks at how the new medicines work in the body. The study consists of two parts. If participants take part in Part 1, they will either get a single dose of NNC0165-1875 or a "dummy" medicine (placebo). If participants take part in Part 2, they will either get a single dose of NNC0165-1875 or "dummy" medicine and also a single dose of semaglutide. Which treatment participants get is decided by chance. For Part 1 participants will get 1 injection. For Part 2 participants will get 2 injections. A study nurse at the clinic will inject the medicine with a thin needle in a skin fold in the stomach. The study will last for about 9 weeks. Participants will have 7 visits to the clinic with the study doctor.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
88
Participants will receive a single dose of subcutaneous (s.c.) NNC0165-1875 injection. The planned doses of NNC0165-1875 are as following: cohort 1 and 7: 0.1 mg, cohort 2 and 8: 0.3 mg, cohort 3 and 9: 0.6 mg, cohort 4 and 10: 1.2 mg, cohort 5 and 11: 2.4 mg and cohort 6: 0.03 mg.
Participants will receive a single dose of s.c. placebo injection.
Participants will receive a single dose of s.c. semaglutide 0.25 mg injection.
Novo Nordisk Investigational Site
Tempe, Arizona, United States
Number of treatment emergent adverse events (TEAEs)
Count of adverse events.
Time frame: Day 1-36
AUC0-∞,1875,SD; the area under the NNC0165-1875 plasma concentration-time curve from time 0 to infinity after a single s.c. dose
Calculated based on plasma NNC0165-1875 measured (nmol\*h/L) in blood.
Time frame: 1-36 days
Cmax,1875,SD; the maximum plasma concentration of NNC0165-1875 after a single s.c. dose
Calculated based on plasma NNC0165-1875 measured (nmol/L) in blood.
Time frame: 1-36 days
AUC0-∞,sema,SD; the area under the semaglutide plasma concentration-time curve from time 0 to infinity after a single s.c. dose
Calculated based on plasma semaglutide measured (nmol\*h/L) in blood.
Time frame: 1-36 days
Cmax,sema,SD; the maximum plasma concentration of semaglutide after a single s.c. dose
Calculated based on plasma semaglutide measured (nmol/L) in blood.
Time frame: 1-36 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.